RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Multiple myeloma (MM) is a common malignant hematology disease. The development of proteasome
inhibitors (PIs) and immunomodulatory drugs (IMiDs) significantly improved the survival of MM
patients. IMiDs have multiple effects in MM therapy. Except for direct cytotoxicity, IMiDs
also play a variety of immune regulatory roles. Lenalidomide, a kind of IMiDs, was usually
used in the therapy of relapsed/refractory MM. The efficacy and safety of RDD (lenalidomide,
pegylated liposomal doxorubicin, dexamethasone) in newly diagnosed patients with MM still
needs to be further validated.